MedTrace Logo

Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine

NCT01023776 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-12-23

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine the amount of live virus that can be recovered from the nose of people who are vaccinated with the licensed live vaccine against H1N1, and to describe the immune response to vaccination.

Conditions

Interventions

BIOLOGICAL

A/California/07/09 live monovalent H1N1 vaccine

0.1mL per nares intranasally, second identical dose given 28 days after first vaccine

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • John J. Treanor, M.D. · University of Rochester

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
32 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-04-30
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01023776 on ClinicalTrials.gov